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http://www.biomedcentral.com/1756-0500/7/347RESEARCH ARTICLE Open AccessInvestigating active ingredients in a complex
intervention: a nested study within the Patient and
Decision Aids (PANDAs) randomised controlled
trial for people with type 2 diabetes
Ian Brown1*, Alastair Bradley2, Chirk Jenn Ng3, Brigitte Colwell2 and Nigel Mathers2Abstract
Background: Randomised trials provide evidence that patient decision aids improve outcomes with respect to
patient knowledge, involvement and satisfaction in decision making. It is less clear how these complex
interventions are implemented within patient-clinician interactions and which components are active for
improving decision processes. To investigate the experiences of using a diabetes treatment decision aid and to
explore how components within a complex intervention influenced the decision making process.
Methods: A pragmatic mixed methods study nested within the PANDAs cluster randomised trial of a patient
decision aid. Themes inductively derived from interviews and observation of consultations with further
triangulation with results of decision quality and involvement measurements and case analyses.
Results: The decision aid intervention was employed flexibly within the consultation with both the patient and
clinician active in marshalling elements. The decision aid improved processing and organization of information
needed for decision making within the consultation interaction. It also improved decision quality by preparing
the patient for active involvement within the clinical consultation.
Conclusion: The intervention was acceptable, flexible and readily implemented in primary care consultations.
The decision aid was effective in facilitating cognitive processing. The intervention also facilitated rehearsal in
preparation for active roles in a shared decision process.
Trial registration: Trials Register Number: ISRCTN14842077. Date registered: 24.06.2010.
Keywords: Patient decision aid, Process evaluation, Type 2 diabetes, Primary careBackground
The concept of shared decision-making between clinicians
and patients is valued in health care systems around the
world [1,2]. An increasing range of interventions that im-
prove shared decision-making have been developed and
evaluated in the last decade [3]. The main focus has been
patient decision aids (PDAs) designed to help patients reach
an informed decision about what is best for them as an indi-
vidual in the face of treatment choices. These PDAs can
function in different media, such as a booklet or web-based* Correspondence: ian.brown@manchester.ac.uk
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reproduction in any medium, provided the orprogramme, which the patient works through, either indi-
vidually or with support and discussion with their clinician.
A systematic review of 86 randomised trials of decision aids
concluded that PDAs improve patient knowledge, involve-
ment and comfort in decision making [4]. It is less clear
what effects these interventions have on patient-clinician
interaction and which components are the essential ingredi-
ents for improving decision processes and outcomes [4].
Decision aids are a complex intervention with several
interacting components, entailing complex behaviours and
a range of effects [5]. In view of their complexity, a degree
of flexibility in their implementation is inevitable. The key
intervention elements, within even a robust evaluation,
may not be readily apparent from trial outcomes data.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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contexts are therefore useful [5].
Type 2 diabetes is a common long-term condition across
the world [6]. In England nearly five per cent of adults have
this condition and the prevalence is increasing [7]. It is
usually controlled initially with lifestyle changes (diet and
physical activity) and oral medications [8]. However, with
disease progression, it is necessary to consider other treat-
ment options, such as insulin therapy, to achieve glycaemic
control. Patients often find it difficult to decide whether or
not to start insulin [9,10]. The decision requires, for ex-
ample, deliberation about the benefits of improved glucose
control with insulin against its side effects such as the risk
of hypoglycaemia and weight gain.
The PANDAs (Patients ANd Decision Aids) Trial evalu-
ated a PDA for patients with diabetes facing decisions about
treatment options, including insulin, in a primary care
setting (NIHR National Trials Register Number 14842077).
The components of the PDA are summarised in Outline of
PANDAs Decision Aid. The intervention design drew on
the Ottawa Decision Support Framework (ODSF), which
identifies determinants of health care decisions potentially
modifiable by the use of a decision aid [11,12]. The ODSF
is based on a range of established cognitive psychological
theories and models to provide a pragmatic model for deci-
sion aid development [13,14]. The PANDAs PDA contains
four contents integrated within a booklet: first, reviewing
information about type 2 diabetes, including its symptoms
and treatment options; second, evidence-based estimates of
the benefits and risks of each treatment option personalised
for the individual patient; third, questions to help patients
clarify their values, preferences, and expectations as regards
these options; and fourth, systematic guidance through the
decision-making process.
Outline of PANDAs Decision Aid
Starting Insulin: Your Choice
Introduction to the decision aid (pages 1–2)
Information (pages 2–6)
 Is there a need to start insulin?
 What happens when people take insulin?
 What are people concerned about when they start
insulin?
 How is diabetes affecting you?
 Do you find it difficult to follow diabetes advice*?
 What are your choices?
Step 1: Learn about the choices (pages 7–10)
 Make no change
 Follow diabetes advice more regularly
 Add insulin
 Summary of the three choices
Step 2: Thinking about what is important to you (page 11)Step 3: What else do you need to make a decision
(page 12–13)
Step 4: What are the next steps? (page 14)
Notes
* the lifestyle and oral medications advised
The PANDAs Trial aimed to evaluate the clinical effect-
iveness of the PDA in improving decision quality (decisional
conflict, knowledge, risk perception and involvement in
decision making) and the feasibility of implementing the
PDA in NHS primary care. A cluster randomised controlled
trial was undertaken in England involving 49 general prac-
tices and 175 patients [15].
This paper describes a nested mixed methods study
undertaken within the intervention arm of the PANDAs
Trial of a PDA for people with type 2 diabetes. The nested
study aimed to investigate the experiences of using a PDA
in routine primary care practice and to explore how com-
ponents within this 'complex intervention' influenced the
decision-making process.
Methods
The nested study drew on guidance [5] and reviews [16] of
methods for embedding a qualitative process study within a
clinical trial. A qualitative design has origins in social
research and typically entails a more emergent, flexible and
inductive approach in contrast to trial methodology. For
example, as described below, our qualitative approach
included purposive sampling and inductive data analyses.
In addition the design drew on a pragmatic mixed
methods approach [17,18] in integrating and combining
quantitative measures, from the main trial, where these were
germane to the process study aims. A pragmatic approach is
an established philosophical and theoretical underpinning
for social research, as employed in health services research,
where the purpose is primarily policy relevant findings. Data
integration is described below. It included, for example, the
integration of qualitative data derived from interview and
observation transcripts with quantitative data derived from
scores of a validated standardised measure of decision
conflict.
Following preliminary analyses data were integrated at
the level of cases with a view to developing a fuller under-
standing of the decision aid intervention in the context of
its implementation. Each case was a unique instance of a
patient and practitioner employing the decision aid in a
consultation and integration of data included a variety of
types of data and time points of data collection to provide
insight on the intervention process. Matrices and threads of
case evidence were employed over several iterations. Initial
themes were tested and refined within and across case data
[19,20]. For example, in testing and refining a theme on
how the decision aid was employed to foreground a deci-
sion making agenda in the consultation. Analyses were
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sources of data converged to support findings (triangula-
tion) [20]. For example, where data from observation
illustrated an initially passive patient becoming more
autonomous within the consultation and this change was
also found in the before and after control preference
scoring.
The main trial was undertaken in South Yorkshire in
England [15]. Participating practices screened computerised
diabetes registers for eligible patients with type 2 diabetes.
People with type 2 diabetes taking at least two oral glucose
lowering drugs at maximum tolerated dose and with a latest
HbA1c > 57 mmol/mol in the preceding six months were
included in the study. Exclusion criteria included those
currently using insulin therapy or people who would have
difficulty participating in a study for reasons of language,
mental health or cognitive impairment. Patients were
initially contacted by letter to participate in the main study
and, once they had agreed to take part, were subsequently
invited to also join the process study.
Following research ethics approval from North Sheffield
Research Ethics Committee, eight pairs of patient-clinician
dyads were recruited from the PANDAs Trial intervention
arm. Recruitment followed a purposive sampling strategy
which aimed to include patients from varied backgrounds,
practice contexts and stages of decision-making [21]. In
parallel, the patients’ primary care clinician for diabetes care
(general practitioner or practice nurse) was also recruited
into the study.
Recruited patients to the process study completed a base-
line questionnaire (as in the main trial) and then systemat-
ically worked through the PDA with the researcher who
provided clarification on any issues raised. This was
followed by a consultation with a clinician in which the
PDA was available to be used by the patient and clinician.
Decision quality was determined using a patient self-
administered questionnaire following the consultation. Two
validated measures of decision quality were employed.
'Decisional Conflict Scale' measures the degree to which
the patient feels uncertain about their decision; a low score
indicates less decisional conflict [22].’Control Preference
Scale’ indicates patients’ preferred role in the decision mak-
ing process; autonomous means patients are more involved
in decision making while passive means less involved [23].
Observation was undertaken via audio recording of the
consultations. Verbatim transcripts of the clinical con-
sultation were analysed for themes and also scored using
a validated scale for observing patient involvement - the
OPTION scale [24,25]. This scale was developed origin-
ally in general practice and is designed to measure the
extent to which clinicians involve patients in decision
making during consultations. To derive a score for the
level of involvement, two researchers from the research
team independently scored each consultation and then indiscussion arrived at an agreed score for each item and
total score.
Semi-structured individual interviews with the patient
and clinician were conducted separately within two weeks
of the consultation (Table 1). The researchers also made
field notes on the practice and consultation contexts. The
qualitative interviews followed a semi-structured topic
guide with open-ended questions to explore the patient’s
and clinician’s views of the PDA and the process of its use
in practice. All qualitative interviews were audio recorded,
transcribed verbatim and QSR NVivo software (version 8)
was used to facilitate data management [26].
Initial analyses of qualitative data followed the iterative
steps established in Framework Analysis [27]. Preliminary
coding was refined over a series of iterations to establish
themes pertinent to study aims [28]. The qualitative data
were then collated with quantitative data, including
measures of decision quality, to facilitate case analyses. The
final stages of analysis involved triangulation of the data to
provide a fuller insight into the experiences of using the
PDA and the components that influenced decision making
[20,29]. This was an iterative process involving the research
team refining and testing the case evidence.
Results
Eight full sets of qualitative and quantitative data were
collected before, during and after a diabetes care consultation
in primary care.
Participants and measures
The patient and clinician characteristics (Table 2) are
reasonably diverse (as intended) and reflective of diabetes
care programmes in primary care. Three female and five
male patients with ages ranging from 39–81 years took part
in consultations provided by a mix of clinicians. Control
preference measures show a spread of degree of preferred
role in decision making across the patients prior to the
consultation. Patients E and G preferred a more passive
role on these measures; patients C, D and F preferred a
more autonomous role.
Consultation times ranged between 4 and 29 minutes
and these times are typical of diabetes care with longer
nurse appointments in comparison to doctors. The
OPTION scores indicated a good degree of patient involve-
ment in decision-making but this varied according to the
role of the clinician with the nurses involving the patients
more than the GPs. Within the OPTION items all clini-
cians scored best in emphasising the need for a decision
and least well on eliciting the patients preferred level of
involvement and method for receiving information to help
them reach a decision. Across the patients there were a
range of decisions reached but generally a low level of
decisional conflict following the consultation - indicating a
greater likelihood that the decision would be implemented.
Table 1 Interview guides
Patients
Could you describe your experience of using the decision aid?
• Probes to explore perceptions of format, language, understanding and most useful sections
Was the decision aid useful in helping you to make a decision about your treatment?
• Probes to explore perceptions of contribution to decision making process
Could you describe your consultation with the doctor/nurse?
• Probes to explore use of decision aid within the consultation and contribution to discussion
Is there anything else that may have helped/hindered with your decision?
Do you have any suggestions for how we can improve the decision aid in the future?
Healthcare professionals
Could you describe your thoughts regarding the decision aid?
• Probes to explore perceptions of most/least useful sections
Could you describe how the consultation went with the patient?
• Probes to explore use of decision aid within the consultation and contribution to discussion and patient understanding
• Probes to compare experiences and difference to the consultation with and without a decision aid
Is there anything else that may have helped/hindered with the decision?
Do you have any suggestions for how we can improve the decision aid in the future?
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also showed good typicality and diversity (as intended) in
relation to the main trial intervention arm. For example,
mean patient ages and consultation times were almost
identical (65.3 years and 15.4 minutes in the cases;
64.5 years and 15.3 minutes in intervention arm); and the
treatment decisions reflected the full range of decisions in
the intervention group with low decisional conflict scores.
Consultation processes
Extracts from consultation observation data are presented in
Table 3 to give a flavour of the interactions and to illustrate
the decision aid intervention processes. The PDA was
referred to within all the consultations but varied greatly
as to whether it was in the background or foregroundTable 2 Participants with consultation and decision character
Patient Gender Control preference
(pre-consultation)
Clinician Consultation
(minutes)
OPTIO
A f collaborative PN 20
B f collaborative GP 13
C f autonomous GP 4
D m autonomous PN 17
E m passive PN 17
F m autonomous PN 29
G m passive PN 16
H m collaborative GP 7
Notes: PN = Practice Nurse, GP = General Practitioner; OPTION (Observing Patient I
score indicate greater patient involvement in decision taking. *Follow advice about
conflict scores: range = 0–100; low score is better; score below 25 associated with im(explicitly part) of discussions. There was an on-going
process of arriving at a shared sense of whether the PDA
should be in the foreground or background. Within this
process two influences were evident. First, how imminent
an important decision was going to be taken (illustrated in
Patient A). If it could be reasonably put off the PDA was left
in the background (Patient B). Second, how open minded
the patient remained about what to do as they took part in
the consultation. If a decision had become clear prior to
consultation the PDA was clearly of less value and moved to
the background in discussions (Patient H) during the con-
sultation. It was otherwise variously marshalled in support
of arguments or to set the agenda or change the subject
(Patients E, G and D), particularly within longer discussions
of lifestyle factors and diabetes.istics
N score Decision Control preference
(post-consultation)
Decision conflict
(post-consultation)
31 Add insulin autonomous 0.00
15 Current advice* collaborative 12.50
10 Current advice* autonomous 0.00
30 Current advice* autonomous 25.00
27 Current advice* autonomous 9.38
28 Not sure autonomous 0.00
34 Make no change collaborative 25.00
15 Add insulin autonomous 0.00
nvolvement) score based on 12 item measure, scores range 0 to 48, higher
current diabetes therapies (oral medication/lifestyle) more regularly. Decision
plementing decisions; score above 37.5 associated with decisional delay.
Table 3 Consultation extracts
Patient A Nurse OK. We’ll have a look at [PDA] together then and then we’ll go back onto the insulin things.
Patient A Yeah, yeah. [Discussion covering main sections of the PDA, then:]
Nurse Great, yeah. Clearly understood what we’re talking about.
Patient A Yeah, yeah.
Nurse And these are the choices that you’ve got haven’t you?
Patient A Yeah, yeah, they are, yeah.
Nurse So having looked at those choices and taking on board that, you’ve come to a decision -
Patient A Well I think I’ll agree to listen to your concerns as well, you know, because I think you’ve more experience, you know,
in sort of dealing with this thing than I have, you know, so if it’s necessary that I need to go on insulin I’m quite prepared to.
B GP How are you getting on?
Patient B I still don’t think I’m any closer to making a decision. I didn’t think I were near enough for that decision yet.
GP So I think we’ve maybe got a bit of scope to increase your medication […] I don’t think you’re absolutely ready to be referred as yet …
C Nurse: How did you find that [PDA], useful?
Patient: Yeah, a couple of times it’s been mentioned to me about going on insulin.
Nurse: Mmm, yes, I know.
Patient: And I’ve always feared it, you know, I’ve feared it
D Nurse And obviously this [PDA] has given you something to think about.
Patient D It doesn’t do a lot for me actually. No. I mean the difference between 22 and 29 -
Nurse But think about – yeah, but if you were one of those three it would be a big difference.
Patient D Yeah, but one of those three could be run over by a bus. I mean that’s what life’s all about. These are probabilities,
you know. […] I’m not going to fight statistics.
E Nurse This [PDA] how have you found it? …
Patient E Ok. You know, I'm fairly positive with most things. [discussion follows with reference to diabetes treatments as structured in PDA]
Patient E So it's my diet that's got to be sorted a bit better.
F Patient F: But I just do feel that one of the reasons the tablets are struggling is because all the things I’m not doing - the stuff we
discussed earlier [in the PDA].
Nurse: That’s it it’s got to be a bit of everything hasn’t it. It’s got to be the correct medication. Diet. Exercise.
Patient F: I’m gonna go back onto the eating regime I was on in 2002 when I lost all the weight.
G Patient G: But I'm finding tablets ok you know.
Nurse: But ok in what way? Because so far they've not brought your sugar level down…
Patient G: They've not made me feel badly at all.
Nurse: And at the moment what do you think the best plan of action would be? […]
Patient G: Definitely diet yeah.
Nurse: Adapting that a little better, try and get your sugar levels down.
Nurse: [later…] Just going back to this [PDA], is it important for you to get your sugar down?
H GP And really I think we’re going to, you know, need insulin to…
Patient H Yeah, that’s fine.
GP … get it …
Patient H Yeah, let’s get on
GP …nicely under control. Err,… [later…]
GP I’m sure they have…
Patient H Yeah. Been through it.
GP …been through all that. What did you think of the [PDA], was it…?
Patient H Yeah, it was good, yeah.
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ledge of diabetes was referred to more than information
quantifying risks. Where the latter became part of the con-
sultation it was not thought to influence decisions (Patient
D). Other components were employed to keep a focus on
the need for a decision and to broadly revise options.
Perceptions of intervention process
In all cases, the patients were engaged in using the PDA
prior to the consultation and it was referred to by both the
patient and clinician in all the consultations. The PDA was
perceived to be valuable by both patients and clinicians and
they found it particularly useful in terms of the ease of
navigation and its full coverage of information (Table 4).
The general perception, particularly among the clinicians,
was that the decision aid booklet helped influence the
decision (Table 4). For example, Patient G and his clinician
clearly identified the decision aid as helpful to reach a
decision not to start insulin. However, half of the patients
saw the PDA as informative but less directly influential on
decision-making. For example, Patient E, continued to defer
to professional advice.
Integrating qualitative and quantitative data refined
understanding of individual processes in implementing the
decision aid (Tables 2, 3, and 4). Patient A made a decision
she was likely to implement within a typical length nurse
consultation. The PDA was employed explicitly to structure
the discussions and the consultation scored highly on pa-
tient involvement. In contrast Patient H made the decision
to add insulin prior to the consultation. The consultationTable 4 Perceptions of the decision aid process
Patient
A I think that’s [the PtDA] let me know what options that I had got, yeah.
B You’ve got it down in writing that and then it’s shown clearly across
the board. So I think that’s very effective as well. I really think it,
it concentrates your mind […] I think it makes you think in depth
about what you really think about it, and you don’t just react
C I’d made the choice to myself, that I were going on this insulin, so I
had to see the doctor […] I confirmed it to myself I was going on it
D I’d made my mind up on this, not 100 per cent, but I’d more or less
made my mind up months and months ago that this was the way I
wanted it to go, otherwise I’d have been on insulin a long while back
E So no matter what this book says at the end of the day,
professional advice is the thing that you really need
F it wouldn’t have persuaded me to not take insulin, but I,
as I say, I’ve learnt things
G Well it helped me to make a decision […] It told me
I didn’t need to go on insulin.with a GP was shorter and less involving and the PDA was
not used to structure discussions but referred to as a
completed step that supported the decision. For both
Patient A and B a revision of symptom control and general
information about diabetes complications appeared to in-
fluence their decision making more than other components
in the PDA.
Other patients (B, C, D, E and G) made decisions to fol-
low current advice more carefully or not change treatments.
The PDA was variously marshalled by both patient and
clinician within the interaction as part of discussions to set a
shared agenda or to support a point of argument. For
example, Patient G was more passive in their control prefer-
ence prior a highly involving consultation with a nurse and
also scored more highly on the decisional conflict scale. The
PDA moved in and out of the consultation discussions
marshalled more by the nurse with respect to glucose
control and more by the patient with respect to lifestyle ap-
proaches to control and symptoms. Agreement was reached
(via the PDA) that current symptoms were related to dia-
betes control and that steps to adapt diet should be taken.
Patient E remained unsure as regards the decision
options after a long and highly involving consultation
with a nurse. This individual with an autonomous control
preference also scored low on the Decisional Conflict
Scale. The consultation data indicated that the PDA was
fully employed and in the same manner as for other
patients (Table 3). Indeed a decision to lose weight was
apparently reached after discussing treatment options
during the consultation.Clinician
she picked up very clearly on your charts that were here […] clearly this
booklet has given her the indication and helped her make the decision
Very [helpful] yes. Yes, it is, and I think you know, like the first couple of
pages is really […] I think that could be rolled out to more of the patients
I think it probably reinforced that he could feel better if his
diabetic control was better
I think it’s fantastic, I really, really do. Not only for the patient, but for
the professional actually going through a consultation. […] It’s given
him a lot of food for thought and I think equipped him with the
right knowledge to go away and make that decision
I think it’s highlighted to him the problems […] seeing the pictures
and the percentages may have stuck in there a little bit […] in this
particular patient, I don’t think it’s added anything to the
consultation, knowing him as I do
Well, definitely [helpful] because previously erm, when insulin’s
been mentioned, it’s no [he wouldn't focus on it as an option]
I think the fact that we'd actually got something to show him some
sort of card, copy of questions relating to him, you know, tailored to
his needs and also then my presentation which perhaps just reinforced
everything. […] It's perhaps not the decision we wanted him to make,
but that may come in future
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Three themes with respect to active components are
presented in Table 5 with supporting data. First, the PDA
raised awareness of the key issues in the choice of
treatment, second, it improved the knowledge necessary for
making the decision; third it provided preparation for
involvement in the consultation. The health information re-
lating to poor diabetes control and current symptoms was
valued and had an impact on the decision-making process.
Several patients seemed unaware of their symptoms related
to diabetes. The provision of personalised information
about morbidity risks of poor diabetes control was valued
by the patients. However, information about the risks and
benefits of each treatment option, including the numerical
risks and pictorial presentation, had less impact on the
consultation interaction (see below). Patients valued their
involvement in decision making and the personalised care
(‘what the decision could mean for me’) which they
received from the clinicians. The PDA was also thought to
have prepared the patient for the consultation, providing a
shared terminology and agenda. In this respect the PDA
was seen as a tool to help the patient and clinician prioritise
the agenda and focus on an issue that might otherwise be
lost within a general discussion.
Discussion
Our mixed methods study nested within the PANDAs Trial
has usefully triangulated qualitative and quantitative data to
explore active elements within a complex decision aid inter-
vention. Strengths of the study are that PANDAs is a typical
decision aid intervention and that, within a pragmatic trial,
an intervention implemented in typical health care settings.
However, the small sample sizes in the nested process study
mean our findings should be viewed as provisional. They
are nevertheless interesting and add to understanding of a
complex intervention. The findings support aspects of the
cognitive underpinnings for decision aid interventions but
also point to other active ingredients that will require
further research to fully be illuminated.Table 5 Perceptions of active components
Theme Illustrative quotes
Challenging preconceived ideas I think it really highlights the p
diabetes, whereas previously I t
[Interview E Clinician] what do
even thought of, so there’s tha
Increasing knowledge base I think she had a better unders
[Interview A Clinician] but I did
[Interview A Patient] I think if y
saying ‘I’m going to have to re
we’re referring you. So I think w
understanding [Interview B Pat
Rehearsal and prompt for agenda setting
and structuring of the consultation
It has guided my consultation
was before [Interview D Clinicia
Patient] I mean he had his ope
that he was quite happy to looThe main trial had shown that the PANDAs PDA is an
effective intervention for general practice and its use leads
to improved decision-making outcomes for patients [15].
The nested study adds evidence of a practical and flexible
intervention readily incorporated into routine practice to
facilitate shared decision-making within a consultation.
There are insights as to how both patient and clinician
can be active in employing its components to facilitate a
shared decision [30].
The PANDAs PDA clearly improves the understanding
and organization of information during the consultation by
allowing the patient and clinician to consider and summar-
ise a range of objective and subjective information. The
elements for them to consider within the decision were,
therefore, easier to remember and focus on in the consult-
ation. However, information about the numerical risks and
benefits was not apparently integrated into the decision-
making. Rather, more descriptive information of the pos-
sible links between current symptoms and glucose control
was more influential. In this respect the PDA may improve
but not substantially alter the broad heuristic thinking that
typically underpins decision making by patients [3].
Most patients with type 2 diabetes have various other
issues aside from glucose control that require attention
within the consultation. The PDA helped by preparing pa-
tients for the likely structure and agenda of the consultation
– thereby enabling better involvement in decision making.
It also appeared to support a more involving style of
consultation encouraging the patient to be more active in
setting the agenda in the interaction. In this respect the
PDA is an intervention facilitative of communication styles
that encourage patient agenda setting and involvement in
decisions [31,32].
Whilst information processing and consultation structur-
ing are clearly active ingredients, other non-cognitive ele-
ments may also be active. For instance, detailed numerical
information appears to be liked by patients as an indicator
of personalised care and less for its value in actually
estimating risks. In effect it works more as social learningroblems that they are experiencing is due to their poorly controlled
hink they just would have thought, oh it’s because I’m getting older
you think of straightway, he’s a druggie, that’s the last thing I want to be
t side of it [Interview D Patient on preconceptions of insulin therapy]
tanding. She certainly was more aware of complications with diabetes.
n’t realise that you could get heart disease through diabetes, you know
ou don’t use the decision aid it’s very sort of doctor looking at figures
fer you’ and then it’s like they don’t know why and all they know is that
hen you use the decision aid I think they actually have much more
ient]
into a more, probably more thorough and more focused path to what it
n] It helped me to understand where she's coming from. [Interview E
n on the desk. So that was sort of an indirect way of letting me know
k at it [Interview G Clinician]
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to observation and modelling as motivators of a behaviour
or action [33]. In contrast cognitive theories emphasise
internal information processing and the logical sifting of
thoughts to arrive at a decision. Personalised risk informa-
tion is active in the intervention because it rewards motiv-
ation to take part in a social decision making process; it is
less apparently active because it facilitates information
processing.
Broadly, therefore, our study supports the underlying
cognitive theoretical models for decision aids [13,14] but
suggests also their value as social encouragement to share
in a decision process and as preparation for active involve-
ment within the consultation interaction. The simple pres-
ence of a tool provides an expectation of involvement and a
more shared agenda which, in turn, alters behaviour. The
OPTION scale has been used with clinicians in primary
care previously [24,25]. Only cautious comparisons are ap-
propriate but it is interesting to note that the scores in these
other studies were substantially lower than that observed in
this study of a decision aid in use. This adds to the evidence
that a decision aid facilitates involvement in the consult-
ation by both parties and contributes to greater autonomy
and satisfaction with the decision by the patient [4].
Wider implementation of PDAs remains a challenge [34].
Shared decision making is not the norm as yet in most
health care systems despite efforts to improve involvement
and patient self-management [35-37]. A number of qualita-
tive studies have explored user and provider perceptions of
implementing decision aids in primary care practice
[38-41]. As in our study there is broad support from
patients for the educational and informational value of
decision aids but greater reservations from healthcare pro-
viders with respect to decision aid costs and practicalities.
Ease of navigation and other design features are critical to
acceptance; as are other factors affecting consultation time
and ease of integration into routine practice [38-41]. In-
volvement of clinicians and patients in the development
stages of a PDA is crucial and this element is emphasised in
International Patient Decision Aid Standards [42].
Another issue is how to present risk information in an
acceptable and engaging form for patients and how this
may influence decision making [43]. The PANDAs PDA
used numbers, words and pictures [44] to convey informa-
tion about the absolute risks of diabetes complications over
five years. The nested study suggests this information had a
mixed reception and did not directly influence decision
making in the way that was anticipated.
Further research should examine which cognitive and
social components of a PDA are most useful with which
category of patients [30]. Patients found the personalised
nature of the PANDAs PDA helpful and it reinforced a
sense of personalised care and therefore commitment to
shared decision making. Further study of how this andother design elements can be integrated into current clin-
ical practice would be useful [45], particularly for under-
standing how an intervention may be more successfully
implemented in different contexts. For example, would an
electronic version of the PANDAs PDA (that can be main-
tained with the electronic patient record) be as effective?
Policy makers, professional leaders and patient groups
would all like to see more effective involvement of patients
in their own care [46,47]. The PANDAs PDA can be
recommended for general practice, particularly within the
context where a decision is imminent. For a patient who is
already confident and autonomous as regards health care
decision making, the PDA can be used within a standard
length consultation. For patients who are less engaged as
regards to decision-making, or feel much undecided, the
PDA should be used in conjunction with a longer and
more involving consultation. The PDA can be used to
organise complex information and prepare patients for
agenda setting within the consultation. It can be used to
reinforce a sense of personalised care, to structure the
decision making communication as well as to focus on
and revise current symptoms. All of which are active
ingredients in helping patients to reach a decision.
Conclusions
Decision aids that can be employed actively and flexibly by
both patients and clinicians within the consultation inter-
action are helpful for implementation. Their design should
of course attend to the information processing needs of
patient and clinician. Further research about other active
intervention elements of motivation and social learning for
a shared social process would be useful.Competing interests
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